DYAI DYADIC INTERNATIONAL INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—
Margins
Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—
Returns
ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.09M | $3.50M |
| Cost of revenue | $2.32M | $1.19M |
| Gross profit | $770,485 | $2.30M |
| R&D expense | $2.15M | $2.04M |
| SG&A expense | $5.76M | $6.13M |
| Operating income | -$7.19M | -$5.90M |
| Pretax income | -$7.33M | -$5.76M |
| Net income | -$7.36M | -$5.81M |
| EPS (basic) | -0.23 | -0.20 |
| EPS (diluted) | -0.23 | -0.20 |
| Weighted avg. shares (diluted) | 32.62M | 29.32M |
| Balance sheet | ||
| Cash & equivalents | $4.62M | $6.51M |
| Short-term investments | $2.70M | $2.76M |
| Receivables | $1.09M | $237,027 |
| Current assets | $9.90M | $9.83M |
| Total assets | $9.95M | $9.93M |
| Current liabilities | $3.69M | $2.45M |
| Total liabilities | $8.71M | $7.46M |
| Shareholders' equity | $1.23M | $2.47M |
| Shares outstanding | 36.19M | 29.84M |
| Cash flow statement | ||
| Operating cash flow | -$5.70M | -$3.97M |
| Investing cash flow | $82,085 | -$1.88M |
| Financing cash flow | $4.96M | $5.85M |
| Stock-based compensation | $930,183 | $1.13M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.